)
NEWS
Media Contacts:
United States
Polina Miklush
Mobile: +1 908 608 7170
Email: polina.miklush@seqirus.com
Seqirus news releases
Seqirus news releases
• Appoints Roberta Duncan as new program lead to drive technology advancement
• Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza
Findings from a new observational safety study conducted in the U.S. found no unexpected adverse pregnancy outcomes in pregnant people who were vaccinated with the cell-based quadrivalent seasonal influenza vaccine during pregnancy.
The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic.
Company announces the publication of new real-world evidence on effectiveness of the MF59® adjuvanted, trivalent influenza vaccine (aTIV).
This news release is intended for business and trade media only.
This news release is intended for business and trade media only.
Seqirus announced today that the U.S. Food and Drug Administration (FDA) has approved the first adjuvanted quadrivalent influenza vaccine, FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted), to help protect adults 65 years and older against seasonal influenza.1